Healthcare leaders from Independent Health, Evry Health, BlueCross BlueShield of Illinois, and Vori Health discuss GLP-1s and their role in addressing the global challenge of obesity while considering the crucial aspect of musculoskeletal (MSK) health. Learn innovative, multidisciplinary strategies you can implement to complement lifestyle interventions and other therapeutic approaches in your organization.
Panelists:
- Martin Burruano, Vice President, Pharmacy Services at Independent Health
- Mary O'Connor, MD, Co-founder and Chief Medical Officer at Vori Health
- Mamata Majmundar, MD, Chief Medical Officer at Evry Health
- Shelley Turk, Divisional Senior Vice President of Health Care Delivery at BlueCross BlueShield of Illinois
Read bios
With glucagon-like peptide-1 agonists (GLP-1s) rapidly transforming obesity care as well as employer and payer bottom lines, it's more important than ever to consider strategies for sustainable impact. Check out our latest white paper which explores the comorbid nature of obesity and pain and the need for holistic, doctor-led care to navigate the complexities of GLP-1s for long-term gains.
